NASDAQ:ANCN - ANCHIANO THERAP/S Stock Price, News & Analysis

-0.07 (-2.87 %)
(As of 08/23/2019 04:00 PM ET)
Today's Range
Now: $2.37
50-Day Range
MA: $3.48
52-Week Range
Now: $2.37
Volume9,101 shs
Average Volume33,094 shs
Market Capitalization$17.59 million
P/E RatioN/A
Dividend YieldN/A
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ANCN



Sales & Book Value

Annual SalesN/A
Book Value$3.35 per share



Market Cap$17.59 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ANCN News and Ratings via Email

Sign-up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.

ANCHIANO THERAP/S (NASDAQ:ANCN) Frequently Asked Questions

What is ANCHIANO THERAP/S's stock symbol?

ANCHIANO THERAP/S trades on the NASDAQ under the ticker symbol "ANCN."

How were ANCHIANO THERAP/S's earnings last quarter?

ANCHIANO THERAP/S (NASDAQ:ANCN) issued its earnings results on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.12. View ANCHIANO THERAP/S's Earnings History.

What price target have analysts set for ANCN?

3 equities research analysts have issued 12-month price targets for ANCHIANO THERAP/S's stock. Their predictions range from $12.00 to $16.00. On average, they expect ANCHIANO THERAP/S's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 490.7% from the stock's current price. View Analyst Price Targets for ANCHIANO THERAP/S.

What is the consensus analysts' recommendation for ANCHIANO THERAP/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANCHIANO THERAP/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANCHIANO THERAP/S.

Has ANCHIANO THERAP/S been receiving favorable news coverage?

Media coverage about ANCN stock has been trending positive on Saturday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ANCHIANO THERAP/S earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for ANCHIANO THERAP/S.

Who are some of ANCHIANO THERAP/S's key competitors?

What other stocks do shareholders of ANCHIANO THERAP/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANCHIANO THERAP/S investors own include Cranswick (CWK), Cairn Energy (CNE), Clarkson (CKN), Charter Court Financial Services Grp (CCFS), Close Brothers Group (CBG), Bodycote (BOY), British American Tobacco Plc Ads (BATS), AstraZeneca (AZN), Avast (AVST) and Asiamet Resources (ARS).

Who are ANCHIANO THERAP/S's key executives?

ANCHIANO THERAP/S's management team includes the folowing people:
  • Dr. Frank G. Haluska, Pres, CEO & Director (Age 60)
  • Mr. Jonathan Burgin, CFO & COO (Age 58)
  • Mr. Ronald K. Knickerbocker, Sr. VP of Clinical Devel. & Data Sciences (Age 53)
  • Prof. Abraham Hochberg, Co-Founder & Chief Scientific Officer (Age 81)
  • Dr. Michal Gilon Ohev-Zion, VP of R&D (Age 41)


(ANCN) raised $35 million in an IPO on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

When did the company's lock-up period expire?

ANCHIANO THERAP/S's lock-up period expired on Monday, August 12th. ANCHIANO THERAP/S had issued 2,652,174 shares in its initial public offering on February 12th. The total size of the offering was $30,500,001 based on an initial share price of $11.50. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

How do I buy shares of ANCHIANO THERAP/S?

Shares of ANCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ANCHIANO THERAP/S's stock price today?

One share of ANCN stock can currently be purchased for approximately $2.37.

How big of a company is ANCHIANO THERAP/S?

ANCHIANO THERAP/S has a market capitalization of $17.59 million. The company earns $-13,280,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. ANCHIANO THERAP/S employs 19 workers across the globe.View Additional Information About ANCHIANO THERAP/S.

What is ANCHIANO THERAP/S's official website?

The official website for ANCHIANO THERAP/S is

How can I contact ANCHIANO THERAP/S?

ANCHIANO THERAP/S's mailing address is 1/3 HIGH-TECH VILLAGE GIVAT RAM P.0. BOX 39264, JERUSALEM L3, 9139102. The company can be reached via phone at 972-2548-6555 or via email at [email protected]

MarketBeat Community Rating for ANCHIANO THERAP/S (NASDAQ ANCN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  59
MarketBeat's community ratings are surveys of what our community members think about ANCHIANO THERAP/S and other stocks. Vote "Outperform" if you believe ANCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/24/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel